MRP8 antibody targets myeloid-related protein 8 (MRP8), also known as S100A8. a calcium-binding protein belonging to the S100 family. MRP8 typically forms a heterodimer with MRP14 (S100A9), collectively termed calprotectin, which plays a critical role in innate immunity. This protein is predominantly expressed in neutrophils, monocytes, and macrophages, and its secretion is upregulated during inflammatory responses, infections, or tissue damage. MRP8 functions as a damage-associated molecular pattern (DAMP) molecule, modulating immune cell recruitment, phagocytosis, and inflammation by interacting with receptors like Toll-like receptor 4 (TLR4) or the receptor for advanced glycation end products (RAGE).
MRP8 antibodies are widely used in research to study its involvement in inflammatory diseases (e.g., rheumatoid arthritis, inflammatory bowel disease), cancer progression (e.g., leukemia, colorectal cancer), and metabolic disorders. Elevated MRP8 levels correlate with disease severity, making it a potential biomarker for diagnosis or therapeutic monitoring. Additionally, MRP8 antibodies aid in immunohistochemistry, flow cytometry, and Western blotting to localize and quantify protein expression in tissues or fluids. Recent studies also explore its role in neutrophil extracellular traps (NETs) and autoimmune pathologies, highlighting its dual role in promoting resolution or exacerbating chronic inflammation. Understanding MRP8 dynamics through antibody-based assays remains pivotal for developing targeted therapies.